Bionaut is a technology company.
Bionaut has raised $8.0M across 1 funding round.
Bionaut has raised $8.0M in total across 1 funding round.
Bionaut has raised $8.0M in total across 1 funding round.
Bionaut's investors include B Capital Group, Endeavor Venture Funds, NFX, Prithvi Ventures.
Bionaut Labs is a biotechnology company developing precision microscale robots, called Bionauts, to deliver biologics or small molecule therapies directly to targeted disease sites in the body, especially hard-to-reach areas like the brain.[1][2][3] These wireless, magnetically controlled devices, smaller than a grain of rice, address limitations of conventional drug delivery, such as the blood-brain barrier, enabling minimally invasive treatments for severe conditions in the $130 billion central nervous system (CNS) market.[3][5] Bionaut primarily serves patients with brain disorders, including neuro-oncology (brain tumors), neurodegenerative diseases, chronic pain, stroke, and epilepsy, while solving problems of low localized efficacy and high systemic side effects from traditional methods.[1][3][4] The company shows strong growth momentum, with 28 patents filed (focusing on medical equipment and procedures), preclinical safety demonstrated in large animals, collaborations with top institutions like Mayo Clinic and Boston Children’s, backing from leading biotech VCs, and preparations for first clinical trials in late 2024.[1][3]
Bionaut Labs was founded in 2016 in Los Angeles, California, emerging from a vision to overcome barriers in localized disease detection and treatment using micro-robotic technology.[1][2] While specific founders are not detailed in available sources, the company originated with a focus on precision microtechnology for healthcare, particularly targeting severe brain disorders where existing therapies fall short due to delivery challenges.[1][3] Early pivotal moments include developing modular Bionaut platforms customizable for various payloads and form factors, filing extensive patents, and securing partnerships with world-leading hospitals like the Mayo Clinic, Boston Children’s, and UC system, which propelled preclinical advancements and VC funding.[3]
Bionaut stands out in the medtech landscape through its innovative, customizable micro-robot platform:
Bionaut rides the nanomedicine and precision medicine wave, fueled by demand for targeted therapies, minimally invasive procedures, and nanosurgery in a market projected to reach $11.1 billion by 2028 at an 11.1% CAGR.[1] Timing is ideal amid advances in AI-driven biotech (e.g., similar to Dyno Therapeutics' AAV vectors) and intraoperative imaging, as aging populations drive CNS disease prevalence—brain tumors, epilepsy, stroke—in a $130B market hampered by delivery barriers.[1][3] Favorable forces include rising R&D in drug delivery and micro-manipulation for materials science/electronics crossover. Bionaut influences the ecosystem by pioneering a new modality that transforms biopharma development, enhances therapeutic indices, and enables in vivo monitoring, potentially accelerating treatments across oncology, neurology, and beyond.[2][4]
Bionaut is poised for clinical breakthroughs, with first-in-human trials slated post-2024 preclinical success, expanding its pipeline from neuro-oncology to broader CNS applications like precision microsurgery and chronic pain management.[3] Trends like AI integration in biotech, modular robotics, and personalized cell therapies will amplify its trajectory, while VC support and hospital ties position it to scale globally. As micro-robots redefine localized healthcare, Bionaut could lead a shift from systemic risks to precise, transformative interventions—unlocking the full potential of precision microtechnology that began with targeting the brain's toughest challenges.[2][5]
Bionaut has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series B in October 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2022 | $8.0M Series B | B Capital Group, Endeavor Venture Funds, NFX, Prithvi Ventures |